Curanex regains Nasdaq $1 bid compliance

Curanex regained Nasdaq minimum bid-price compliance after a 1-for-20 reverse stock split completed on August 20, 2026.

Rhea-AI Filing Summary

Curanex Pharmaceuticals Inc (CURX) reports that it has regained compliance with Nasdaq’s minimum bid price requirement. The company had received a notice on November 5, 2025 that its stock traded below the required $1.00 closing bid price for 30 consecutive business days under Nasdaq Listing Rule 5550(a)(2).

On August 20, 2026, Curanex implemented a 1-for-20 reverse stock split of its outstanding common shares to address this issue. Nasdaq staff subsequently confirmed that from August 20, 2026 through September 2, 2026, the closing bid price was at or above $1.00 for 10 consecutive business days, so the company is now back in full compliance and the matter is considered closed.

Positive

• Regained Nasdaq compliance: After a 1-for-20 reverse stock split on August 20, 2026, Curanex’s stock closed at or above $1.00 for 10 consecutive business days, and Nasdaq confirmed the company is back in compliance with Listing Rule 5550(a)(2), closing the prior delisting matter.

Negative

• None.

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Key Figures

Reverse stock split ratio: 1-for-20 Minimum bid price requirement: $1.00 per share Bid-price compliance period: 10 consecutive business days +2 more

5 metrics

Reverse stock split ratio 1-for-20 Reverse stock split of outstanding common stock effective August 20, 2026

Minimum bid price requirement $1.00 per share Nasdaq Listing Rule 5550(a)(2) minimum closing bid for continued listing

Bid-price compliance period 10 consecutive business days Closing bid price at or above $1.00 from August 20, 2026 to September 2, 2026

Initial deficiency notice date November 5, 2025 Date Nasdaq Listing Qualifications Department notified Curanex of bid-price deficiency

Compliance determination date September 3, 2026 Date Nasdaq staff notified Curanex that it regained compliance

Key Terms

reverse stock split, Nasdaq Listing Rule 5550(a)(2), Listing Qualifications Department, minimum bid price

4 terms

reverse stock split financial

"On August 20, 2026, the Company effected a 1-for-20 reverse stock split"

A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.

Nasdaq Listing Rule 5550(a)(2) regulatory

"failed to maintain a minimum bid price of $1.00 ... as required by Nasdaq Listing Rule 5550(a)(2)"

Listing Qualifications Department regulatory

"the Company was notified by the Listing Qualifications Department of The Nasdaq Stock Market LLC"

A listing qualifications department is the part of a stock exchange that checks whether a company meets the exchange’s rules for being listed and staying listed. Think of it as a gatekeeper or building inspector: it reviews financial statements, disclosure practices and corporate governance, flags problems and can require fixes or remove a company’s shares. Investors care because its decisions affect whether a stock remains tradable and how much trust to place in a company’s reporting.

minimum bid price financial

"failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days"

The minimum bid price is the lowest share price that a market, regulator, or specific offering will accept for a trade, listing, or auction—think of it as a reserve or floor that a stock must meet to qualify for certain actions. It matters to investors because falling below that floor can limit trading options, trigger compliance measures or delisting risks, and affect liquidity and the perceived value of a holding, much like a reserve price in an auction sets the baseline for a sale.

Stock Split

1-for-20 reverse split · Effective August 20, 2026

Split Ratio 1-for-20 reverse split

Effective Date August 20, 2026

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What Nasdaq compliance update did CURX announce on September 3, 2026?

Curanex announced that Nasdaq staff determined the company has regained compliance with Nasdaq Listing Rule 5550(a)(2) after its stock maintained a closing bid price of at least $1.00 for 10 consecutive business days ending September 2, 2026.

Why did CURX conduct a 1-for-20 reverse stock split?

Curanex conducted a 1-for-20 reverse stock split of its outstanding common stock on August 20, 2026 specifically to help regain compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum $1.00 bid price for continued trading on The Nasdaq Capital Market.

When did CURX first receive a Nasdaq minimum bid-price deficiency notice?

Curanex received a deficiency notice from Nasdaq’s Listing Qualifications Department on November 5, 2025, stating that its common stock had failed to maintain a minimum $1.00 bid price for 30 consecutive business days as required for continued listing.

Over what period did CURX’s stock meet Nasdaq’s $1.00 minimum bid requirement?

Nasdaq staff determined that from August 20, 2026 through September 2, 2026, Curanex’s common stock had a closing bid price of $1.00 or greater for 10 consecutive business days, satisfying the minimum bid requirement.

Is the Nasdaq bid-price compliance matter for CURX now resolved?

Yes. Nasdaq staff notified Curanex on September 3, 2026 that it has regained compliance with Listing Rule 5550(a)(2), and the company states that this minimum bid-price matter is now closed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/04/2026 - 04:16 PM EDT Accepted by SEC EDGAR 09/04/2026 - 04:15 PM EDT Learn about SEC filing dates

false 0002025942 0002025942 2026-09-03 2026-09-03 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 3, 2026

Curanex Pharmaceuticals Inc

(Exact name of registrant as specified in its charter)

Nevada		001-42815		83-0741390
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

2 Jericho Plaza, Suite 101B Jericho, NY		11753
(Address of principal executive offices)		(Zip Code)

(718) 673-6078

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of exchange on which registered
Common Stock, par value $0.0001 per share		CURX		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

As previously disclosed by Curanex Pharmaceuticals Inc (the “Company”), on November 5, 2025, the Company was notified by the Listing Qualifications Department of The Nasdaq Stock Market LLC (the “Nasdaq Staff”) that the Company failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days as required by Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. On August 20, 2026, the Company effected a 1-for-20 reverse stock split of its outstanding shares of common stock for the purpose of regaining compliance with the Nasdaq Listing Rule 5550(a)(2).

On September 3, 2026, the Nasdaq Staff notified the Company that it has determined that for the last 10 consecutive business days, from August 20, 2026 to September 2, 2026, the closing bid price of the Company’s common stock has been at $1.00 per share or greater. Accordingly, the Company has regained compliance with Listing Rule 5550(a)(2), and this matter is now closed.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Curanex Pharmaceuticals Inc
Date: September 4, 2026	By:	/s/ Jun Liu
	Name:	Jun Liu
	Title:	Chief Executive Officer

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL SCHEMA FILE 3.0 KB
• EX-101 XBRL LABEL FILE 33.4 KB
• EX-101 XBRL PRESENTATION FILE 21.8 KB